Howe & Rusling’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Howe & Rusling’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-800	Closed	-$43K	–	909
2017 Q3	$43K	Sell	800 -300	-27%	-$17.6K	0.01%	320
2017 Q2	$62K	Sell	1,100 -200	-15%	-$8.01K	0.01%	248
2017 Q1	$51K	Buy	1,300 +210	+19%	+$6.69K	0.01%	260
2016 Q4	$24K	Sell	1,090 -10	-0.9%	-$195	0.01%	340
2016 Q3	$25K	Buy	+1,100	New	+$25.8K	0.01%	339

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

KCM

Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return

Howe & Rusling's PTLA Position: Q4 2017 in Review

Howe & Rusling sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q4 2017, closing a stake of 800 shares — an estimated $43K sold.

Howe & Rusling first reported a position in PTLA in Q3 2016 and held it in 5 quarters. The position peaked at $62K in Q2 2017. 215 funds tracked by Wall St. Rank hold PTLA as of Q4 2017.

Howe & Rusling reported no remaining Portola Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
Howe & Rusling sold 800 Portola Pharmaceuticals, Inc. shares in Q4 2017, an estimated $43K.
Howe & Rusling first reported a position in Portola Pharmaceuticals, Inc. in Q3 2016 and held it in 5 quarters.
Howe & Rusling's Portola Pharmaceuticals, Inc. position peaked at $62K in Q2 2017.
215 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q4 2017.

Based on Howe & Rusling's 13F filing for Q4 2017, filed 24 Jan 2018.